Skip Navigation
Department of Health and Human Services www.hhs.gov
 
Slide Tray
0 slides

Return to Slide Library

Slides

Add Presentation to Slide Tray Presentation:

Treatment for Hepatitis C Virus Infection in Adults: Comparative Effectiveness

Slides: 13–24 of 34

Triple Therapy Versus Dual Therapy Containing Boceprevir for Patients With Hepatitis C Virus Genotype 1 Infection

Triple Therapy Containing Telaprevir Versus Dual Therapy for Patients With HCV Genotype 1 Infection (1 of 2)

Triple Therapy Containing Telaprevir Versus Dual Therapy for Patients With HCV Genotype 1 Infection (2 of 2)

Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b (1 of 2)

Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b (2 of 2)

Response Rates in Patients With HCV Genotype 2 or 3 Infection According to Duration of Dual Therapy

Response of Patients With HCV Genotype 2 or 3 Infection According to Dosage of Dual Therapy

SVR After Antiviral Therapy and Clinical Outcomes in Patients With Chronic HCV Infection

Triple Therapy With Boceprevir Versus Dual Therapy in Patients With HCV Genotype 1 Infection: Adverse Effects

Triple Therapy With Telaprevir Versus Dual Therapy in Patients With HCV Genotype 1 Infection: Adverse Effects

Dual Therapy Containing Pegylated Interferon Alfa-2a Versus Dual Therapy Containing Pegylated Interferon Alfa-2b: Adverse Effects

Other Key Findings of This Review

Pages: Previous 1 [2] 3 Next